A Systematic Review of Amnestic and Non-Amnestic Mild Cognitive Impairment Induced by Anticholinergic, Antihistamine, GABAergic and Opioid Drugs
- 867 Downloads
Mild cognitive deficits are experienced by 18% of community-dwelling older adults, many of whom do not progress to dementia. The effect of commonly used medication on subtle impairments in cognitive function may be under-recognized.
The aim of the review was to examine the evidence attributing amnestic or non-amnestic cognitive impairment to the use of medication with anticholinergic, antihistamine, GABAergic or opioid effects.
MEDLINE and EMBASE were searched for randomized, doubleblind, placebo-controlled trials of adults without underlying central nervous system disorders who underwent detailed neuropsychological testing prior to and after oral administration of drugs affecting cholinergic, histaminergic, GABAergic or opioid receptor pathways. Seventy-eight studies were identified, reporting 162 trials testing medication from the four targeted drug classes. Two investigators independently appraised study quality and extracted relevant data on the occurrence of amnestic, non-amnestic or combined cognitive deficits induced by each drug class. Only trials using validated neuropsychological tests were included. Quality of the evidence for each drug class was assessed based on consistency of results across trials and the presence of a dose-response gradient.
In studies of short-, intermediate- and long-acting benzodiazepine drugs (n = 68 trials), these drugs consistently induced both amnestic and non-amnestic cognitive impairments, with evidence of a dose-response relationship. H1-antihistamine agents (n = 12) and tricyclic antidepressants (n = 15) induced non-amnestic deficits in attention and information processing. Non-benzodiazepine derivatives (n = 29) also produced combined deficits, but less consistently than benzodiazepine drugs. The evidence was inconclusive for the type of cognitive impairment induced by different bladder relaxant antimuscarinics (n = 9) as well as for narcotic agents (n = 5) and antipsychotics (n = 5). Among healthy volunteers >60 years of age, low doses of commonly used medications such as lorazepam 0.5 mg, oxybutynin immediate release 5 mg and oxycodone 10 mg produced combined deficits.
Non-amnestic mild cognitive deficits are consistently induced by first-generation antihistamines and tricyclic antidepressants, while benzodiazepines provoke combined amnestic and non-amnestic impairments. Risk-benefit considerations should be discussed with patients in order to enable an informed choice about drug discontinuation or substitution to potentially reverse cognitive adverse effects.
KeywordsMild Cognitive Impairment Neuropsychological Test Zolpidem Oxybutynin Desloratadine
We gratefully acknowledge the assistance of Audrey Attia, Marion Guillemont, Jean-Francois Cabana, Thomas Jubault and Don Sheppard in the preparation of this manuscript.
This work was sponsored by The Michel Saucier Endowed Chair in Geriatric Pharmacology, Health and Aging, from the Faculty of Pharmacy, Université de Montréal. The sponsors had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review and approval of the manuscript.
The financial disclosures for the authors are as follows: Cara Tannenbaum was supported by The Michel Saucier Endowed Chair in Geriatric Pharmacology, Health and Aging, from the Faculty of Pharmacy, Université de Montréal and by a junior researcher award from the Fondation de Recherche en Santé du Québec. She declares having received honoraria and/or consulting fees from Allergan Inc., Astellas, Ferring and Pfizer during the past 3 years. Amélie Paquette was supported by the Canadian Institutes of Health grant 108262. Ryan Carnahan was supported by an Agency for Healthcare Research and Quality (AHRQ) Centers for Education and Research on Therapeutics cooperative agreement ♯5 U18 HSO16094 (the Iowa Older Adults CERT). He has previously received research support from Eli Lilly and Co., Forest Laboratories, Wyeth and Boehringer Ingelheim. All other authors declare that they have received no support from any organization for the submitted work, have no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years and have no other relationships or activities that could appear to have influenced the submitted work.
Contributions: Cara Tannenbaum had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Cara Tannenbaum, Amélie Paquette and Ryan Carnahan contributed to the design of the study. All authors contributed to the data collection, management, analysis and interpretation of the data, and the preparation and review of the manuscript.
- 16.Waxman S. Clinical neuroanatomy. 26th ed. Columbus (OH): The McGraw-Hill Companies, 2009.Google Scholar
- 17.Nestler EJ, Hyman SE, Malenka RC. Molecular neuropharmacology: a foundation for clinical neuroscience. 2nd ed. Columbus (OH): The McGraw-Hill Companies, 2009.Google Scholar
- 23.Bloom FE. Neurotransmission and the central nervous system. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill Companies, 2006: 317–39.Google Scholar
- 24.Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties (CPS 2010). Toronto (ON): Webcom Inc., 2010.Google Scholar
- 25.Lacy CF, Armstrong LL, Goldman MP, et al. Drug information handbook (with international trade name index): 2009–2010. 18th ed. Hudson (OH): Lexi-Comp, 2009.Google Scholar
- 26.Lezak MD, Howieson DB, Loring DW, editors. Neuropsychological assessment. 4th ed. New York: Oxford University Press, 2004.Google Scholar
- 28.Loke YK, Price D, Herxheimer A. Chapter 14: adverse effects. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 [online]. Available from URL: http://www.cochrane-handbook.org [Accessed 2012 Jun 27].
- 34.Greenblatt DJ, Harmatz JS, Engelhardt N, et al. Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics: flurazepam, temazepam, and triazolam [published erratum appears in Arch Gen Psychiatry 1989 Sep; 46 (9): 793]. Arch Gen Psych 1989; 46 (4): 326–32.CrossRefGoogle Scholar
- 36.Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin PharmacolTher 2004; 76 (5): 467–79.Google Scholar
- 45.Allain H, Tessier C, Bentue-Ferrer D, et al. Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers. Psychopharmacology (Berl) 2003; 165 (4): 419–29.Google Scholar
- 83.Timoshanko A, Stough C, Vitetta L, et al. A preliminary investigation on the acute pharmacodynamic effects of hypericum on cognitive an psychomotor performance. BehavPharmacol 2001; 12: 635–40.Google Scholar